Bayer G4A partners with Wellthy Therapeutics

New Delhi: Digital chronic disease management firm Wellthy Therapeutics on Friday announced its partnership with German life sciences group Bayer G4A to improve its product, regulatory and commercialization capabilities while exploring areas of collaboration.

According to Global Head of Bayer G4A Digital Health, Eugene Borukhovich, advancements in digital therapeutics over the last few years has been enabling an integrated health approach for and with the patients.

“We look forward to supporting the advancement of their patient-centric, outcomes-focused approach to care, and explore opportunities to collaborate,” he added.

Speaking on the partnership, Abhishek Shah, CEO & Co-Founder, Wellthy Therapeutics, said, “We are humbled and excited to begin this journey with Bayer, to improve our product, strengthen our company and develop go-to-market solutions that accelerate our journey to bring digital therapeutics to patients worldwide.”